ArticleBMJ open gastroenterology2026
Regional fat distribution as a novel predictor of fracture risk in inflammatory bowel disease: a DXA-based cohort study.
Article in BMJ open gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether dual-energy X-ray absorptiometry (DXA)-derived femoral and abdominal fat percentage was independently associated with fracture history in adults with inflammatory bowel disease (IBD), with a focus on the glucocorticoid-treated IBD population.
methodsA retrospective cohort study of adults with a confirmed diagnosis of IBD underwent clinically recommended DXA scanning to quantify abdominal and femoral fat mass, bone mineral density (BMD) and total body composition between June 2004 and February 2024 in northwest England. Fracture history was the main outcome. After controlling for hip lean mass, body mass index (BMI), BMD, comorbidities and glucocorticoid exposure, multivariable logistic regression models assessed relationships between regional fat percentages and fracture history. To determine if the association was independent of peripheral lean mass, a subgroup analysis of 300 glucocorticoid-exposed patients and a sensitivity model incorporating hip lean mass were performed.
resultsA total of 1302 patients with IBD underwent DXA scanning. Abdominal fat percentage showed a positive correlation throughout the full cohort (OR 1.02, 95% CI 1.001 to 1.037). The correlation remained in patients receiving glucocorticoids (OR 1.06, 95% CI 1.01 to 1.11) and in the lean-mass sensitivity model (OR 1.05, 95% CI 1.01 to 1.09). In all models, there was no correlation between the femoral fat percentage and fracture history. In the full cohort, low BMI was linked to fracture history (OR 2.48, 95% CI 1.02 to 6.04), although BMI (continuous) was only negatively correlated with glucocorticoid exposure (OR 0.91, 95% CI 0.84 to 0.99). After controlling for hip lean mass, BMI and BMD, and glucocorticoid exposure, the link between abdominal fat remained strong.
conclusionThe only regional body composition parameter that was consistently linked to fracture history in patients with IBD, including those receiving glucocorticoids, was abdominal fat percentage. This association held regardless of BMI, BMD and peripheral lean mass. According to these findings, skeletal vulnerability in IBD is linked to this phenotype of abdominal adiposity. To assess potential clinical value and show temporal correlations, prospective studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.